SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC).

Authors

J. Hecht

Jonsson Comprehensive Cancer Center, University of

J. Hecht , Allen Cohn , Shaker Dakhil , Mansoor Saleh , Bilal Piperdi , Vivian Jean Cline-Burkhardt , Ying Tian , William Go

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2013 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Cancers of the Colon and Rectum

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT00418938

Citation

J Clin Oncol 31, 2013 (suppl 4; abstr454)

DOI

10.1200/jco.2013.31.4_suppl.454

Abstract #

454

Poster Bd #

C10

Abstract Disclosures

FEATURED

SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC).